The rapid evolution of anti-cancer therapies has significantly improved outcomes for patients with malignancies. However, these advances have also been accompanied by a rise in nephrotoxicity associated with anti-cancer therapies.
Acute kidney injury (AKI), chronic kidney disease (CKD), hypertension, proteinuria, and electrolyte disorders are increasingly recognized complications associated with conventional cytotoxic chemotherapy, targeted agents, and immunotherapies. These renal toxicities not only impact patient quality of life but may also compromise cancer treatment by necessitating dose reductions or discontinuation.
Kidney International published a clinical update in Research Highlights on 20 Mar 2026.
The item focuses on Cancer Therapy and the Kidney.
Review the original article for the full source wording and details.